Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Current Liabilities for 6 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 53.88% to $20.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Dec 2025, down 53.88% year-over-year, with the annual reading at $20.9 million for FY2025, 53.88% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $20.9 million at Lexicon Pharmaceuticals, down from $21.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $110.7 million in Q1 2025, with the low at $20.4 million in Q1 2023.
  • Average Total Current Liabilities over 3 years is $35.9 million, with a median of $29.7 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 373.07% in 2025, while the deepest fall reached 53.88% in 2025.
  • Over 3 years, Total Current Liabilities stood at $31.5 million in 2023, then surged by 43.43% to $45.2 million in 2024, then tumbled by 53.88% to $20.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $20.9 million, $21.7 million, and $34.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.